系统性红斑狼疮临床建模:相似性、差异与成功案例
该综述讨论小鼠SLE模型在疾病发病机制研究、遗传易感位点与药物靶点识别及新疗法临床前测试中的价值,指出尽管小鼠研究结果有前景,许多新药未达临床终点,可能因疾病多基因 predisposición 与环境因素导致异质性;主张靶向治疗时代需选择最合适模型并识别可能应答患者。
要点
- 小鼠SLE模型是研究发病机制、遗传易感位点和药物靶点及临床前测试的重要工具。
- 许多新药在小鼠研究有前景但未达临床终点,可能与疾病复杂性和异质性有关。
- 靶向治疗需选择最合适的小鼠模型并识别最可能应答的患者。
核心结论
- 小鼠SLE模型对广谱免疫抑制剂评估较成功,但靶向治疗时代需选择最合适模型并识别可能应答患者。
研究设计与样本
- 综述性文章,讨论小鼠SLE模型在疾病研究和新药临床前测试中的应用与局限。
主要发现
- 每个小鼠模型仅重现狼疮有限方面,尤其疾病进展机制。
- 许多新药在小鼠研究有前景但未达临床终点,可能因疾病多基因 predisposición 和环境因素导致异质性。
临床怎么用
- 靶向治疗研发中应根据机制选择最合适小鼠模型进行测试。
- 临床前研究需考虑模型局限性并致力于识别最可能应答的患者。
局限性
- 小鼠模型仅重现狼疮有限方面,尤其疾病进展机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mouse models of SLE have been indispensable tools to study disease pathogenesis, to identify genetic susceptibility loci and targets for drug development, and for preclinical testing of novel therapeutics. Recent insights into immunological mechanisms of disease progression have boosted a revival in SLE drug development. Despite promising results in mouse studies, many novel drugs have failed to meet clinical end points. This is probably because of the complexity of the disease, which is driven by polygenic predisposition and diverse environmental factors, resulting in a heterogeneous clinical presentation. Each mouse model recapitulates limited aspects of lupus, especially in terms of the mechanism underlying disease progression. The main mouse models have been fairly successful for the evaluation of broad-acting immunosuppressants. However, the advent of targeted therapeutics calls for a selection of the most appropriate model(s) for testing and, ultimately, identification of patients who will be most likely to respond.
引用
- Celhar T, Fairhurst AM. Modelling clinical systemic lupus erythematosus: similarities, differences and success stories. Rheumatology (Oxford). 2017. PMID: 28013204. doi:10.1093/rheumatology/kew400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。